CORD files for premarket FDA approval for cataract treatment lens

Cumming Ophthalmic Research and Development has filed an application for premarket approval with the U.S. Food and Drug Administration for a lens to help treat cataracts. 

Advertisement

The Model SC9 intraocular lens is designed to treat cataract patients with a single focus spherical optic and rigid structure in order to position the optic to provide intermediate vision. 

CORD has filed for the premarket application on the results of 300 patients who’ve received the lens and been monitored for a minimum of one year. 

The lens was designed by Stuart Cumming, MD, who previously designed the patented Crystalens, which was approved by the FDA in 2003.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

  • New Providence, N.J.-based PRISM Vision Group, a provider of ophthalmology practice administrative services, has acquired Garden City, N.Y.-based Spectrum Vision…

  • Vision Innovation Partners has opened the Maryland Vision Institute Surgical Center, an ophthalmology ASC in Frederick, Md. The Annapolis, Md.-based…

Advertisement

Comments are closed.